Taro Pharmaceutical Industries (TARO)
(Real Time Quote from BATS)
$42.54 USD
+0.12 (0.28%)
Updated May 21, 2024 03:54 PM ET
After-Market: $42.60 +0.06 (0.14%) 4:10 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TARO 42.54 +0.12(0.28%)
Will TARO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TARO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARO
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
TARO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
Other News for TARO
Taro Pharmaceutical Reports Strong Fiscal Year
Taro: Fiscal Q4 Earnings Snapshot
Taro Provides Results for Year Ended March 31, 2024
TARO Stock Earnings: Taro Pharmaceutical Indus Reported Results for Q4 2024
Taro Pharmaceutical GAAP EPS of $0.40 beats by $0.09, revenue of $164.94M beats by $8.88M